PNEUMOCELL - Conjugated Pneumococcal Vaccination in Patients With Immunoglobulin G-deficiency

Ten patients with Immunoglobulin G1 and/or Immunoglobulin G2 deficiency will be enrolled together with 10 age and sex- matched controls. Blood-samples will be drawn at base-line and after 1, 2 and 4 weeks post-vaccination. Serum will be analyzed for opsonophagocytic antibodies. Peripheral blood monocytic cells (PBMCs) will be isolated, frozen and later analyzed for all time-points simultaneously. PBMCs will be stimulated with vaccine-antigens for 3-5 days and cellular activation markers will be measured together with cytokines (Interferon-gamma, Interleukin (IL)-5, IL-13, IL-10, IL-17, IL-22). In addition, levels of antimicrobial peptides in nasal fluid will be measured at baseline and after 4 weeks post-vaccination.

Inclusion criteria

• Immunoglobulin gamma-deficiency: Immunoglobulin gamma 1-deficiency < 2,8 g/L and/or Immunoglobulin gamma 2-deficiency < 1,15 g/L
• Age 18-65

Exclusion criteria

• Immunoglobulin gamma-substitution for 6 months prior to study inclusion
• Prevenar7 or Prevenar13 given prior to study inclusion.
• Pneumovax given during a 2 year period prior to study inclusion
• Pregnancy or planning to become pregnant during the study period (4 weeks)
• Taking part in another clinical study involving drugs or vaccinations during the study period (4 weeks).
• Taking systemic steroids, Non steroidal anti inflammatory drugs (NSAID) or immunosuppressive drugs.
• Being allergic to any substance in the vaccine.
• Acute and ongoing disease with high fever.
• Thrombocytopenia (< 100x109/L).
• Coagulopathy
• Breastfeeding a baby
• The healthy controls should not have any disease with effects on the immune-system